Gilead Sciences, Inc. (NASDAQ:GILD) Stake Lessened by Lmcg Investments LLC

Lmcg Investments LLC lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 102,756 shares of the biopharmaceutical company’s stock after selling 971 shares during the period. Lmcg Investments LLC’s holdings in Gilead Sciences were worth $7,050,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Renaissance Technologies LLC increased its stake in Gilead Sciences by 17.1% during the second quarter. Renaissance Technologies LLC now owns 5,057,598 shares of the biopharmaceutical company’s stock valued at $347,002,000 after purchasing an additional 739,948 shares during the last quarter. Citizens Financial Group Inc. RI increased its stake in Gilead Sciences by 36.1% during the second quarter. Citizens Financial Group Inc. RI now owns 5,984 shares of the biopharmaceutical company’s stock valued at $411,000 after purchasing an additional 1,588 shares during the last quarter. One Capital Management LLC increased its stake in Gilead Sciences by 36.8% during the second quarter. One Capital Management LLC now owns 5,800 shares of the biopharmaceutical company’s stock valued at $398,000 after purchasing an additional 1,560 shares during the last quarter. Sierra Summit Advisors LLC bought a new stake in Gilead Sciences during the second quarter valued at $783,000. Finally, Dimensional Fund Advisors LP increased its stake in Gilead Sciences by 2.6% during the second quarter. Dimensional Fund Advisors LP now owns 10,412,413 shares of the biopharmaceutical company’s stock valued at $714,421,000 after purchasing an additional 268,208 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

GILD stock opened at $83.16 on Tuesday. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $87.86. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18. The company has a market capitalization of $103.53 billion, a P/E ratio of 231.00, a PEG ratio of 2.80 and a beta of 0.18. The company has a 50-day simple moving average of $75.79 and a 200 day simple moving average of $70.92.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The company had revenue of $6.95 billion during the quarter, compared to the consensus estimate of $6.64 billion. Sell-side analysts predict that Gilead Sciences, Inc. will post 3.78 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 27th. Shareholders of record on Friday, September 13th will be issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 3.70%. The ex-dividend date of this dividend is Friday, September 13th. Gilead Sciences’s payout ratio is 855.56%.

Analyst Ratings Changes

Several research firms have weighed in on GILD. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Thursday, August 15th. BMO Capital Markets boosted their target price on shares of Gilead Sciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Evercore ISI upgraded shares of Gilead Sciences to a “strong-buy” rating in a research report on Friday, August 9th. Royal Bank of Canada upped their price target on shares of Gilead Sciences from $72.00 to $74.00 and gave the stock a “sector perform” rating in a research report on Wednesday, September 4th. Finally, Robert W. Baird restated a “neutral” rating and set a $80.00 price target on shares of Gilead Sciences in a research report on Thursday, June 20th. Twelve research analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $82.06.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total value of $406,150.20. Following the completion of the sale, the insider now directly owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total value of $406,150.20. Following the completion of the sale, the insider now directly owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the sale, the insider now owns 96,380 shares in the company, valued at approximately $6,614,559.40. The disclosure for this sale can be found here. In the last three months, insiders sold 36,847 shares of company stock valued at $3,002,940. 0.16% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.